News & Events

• October 26, 2023
  

  C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement

  TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data......
• October 3, 2023
  

  C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research

  TUCSON, Ariz., October. 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Conference in September, bringing together leading experts, pharmaceutical industry leaders, regulatory agencies, and patient advocates to have a dynamic dialogue about the latest advancements in rare disease research and drug development. The three-day conference, held at......
• September 12, 2023
  

  C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource

  The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development.   TUCSON, Ariz., September 12, 2023 — The Rare Disease Clinical Outcome Assessment (COA) Consortium at Critical Path Institute (C-Path), a public-private partnership focused on optimizing COA selection during drug development for rare diseases, today announced the launch......
• August 15, 2023
  

  NORDs’ IAMRARE Registry Contributes Two New Datasets to C-Path’s RDCA-DAP, Boosting Rare Disease Research and Therapeutic Advancement

  TUCSON, Ariz., August 15, 2023 — Critical Path Institute (C-Path) announced today that the National Organization for Rare Disorders (NORD), a founding partner of the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), is integrating two new datasets to the platform. The FD/MAS Alliance and A Cure in Sight (ACIS) join five other IAMRARE® registries......
• July 19, 2023
  

  The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development

  TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path. Angelman......